Helicobacter pylori eradication can induce platelet recovery in idiopathic thrombocytopenic purpura

Blood ◽  
2001 ◽  
Vol 97 (3) ◽  
pp. 812-814 ◽  
Author(s):  
Giovanni Emilia ◽  
Giuseppe Longo ◽  
Mario Luppi ◽  
Giovanna Gandini ◽  
Monica Morselli ◽  
...  
Keyword(s):  
Idiopathic Thrombocytopenic Purpura ◽  
Breath Test ◽  
Complete Response ◽  
Urea Breath Test ◽  
Thrombocytopenic Purpura ◽  
Platelet Recovery ◽  
Helicobacter Pylori Eradication ◽  
13C Urea Breath Test ◽  
H Pylori ◽  
New Good

Abstract Recent reports have suggested an association betweenHelicobacter pylori infection and idiopathic thrombocytopenic purpura (ITP). The prevalence of H pyloriinfection and the effect of its eradication in a series of 30 ITP patients were investigated. H pylori infection has been documented in 13 patients (43.33%) by 13C urea breath test and confirmed by histologic examination. Bacterium eradication with antibiotics, obtained in 12 of 13 infected patients (92.3%), led to a complete response in 4 (33.33%) and to a partial response (platelets 90 × 109/L-120 × 109/L) in 2 (16.66%). The response was maintained for a median of 8.33 months, but 1 patient relapsed 7 months after eradication. Search for H pyloriinfection seems appropriate in ITP patients at diagnosis. Bacterium eradication provides a new good option for a nonimmunosuppressive treatment in some ITP patients.

The Clinical Efficacy of Helicobacter pylori Eradication in Patients with Helicobacter pylori-Positive Chronic Thrombocytopenic Purpura.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4002-4002 ◽  
Author(s):  
Seung-Hyun Nam ◽  
Bong-Seog Kim ◽  
Jae Hoon Lee ◽  
Hong Suk Song ◽  
Sung-Hwa Bae ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Platelet Count ◽  
Breath Test ◽  
Urea Breath Test ◽  
Rapid Urease Test ◽  
Thrombocytopenic Purpura ◽  
Platelet Recovery ◽  
Chronic Itp ◽  
Urease Test ◽  
H Pylori

Abstract Background: Helicobacter pylori (H pylori) has been implicated in the pathogenesis of some autoimmune diseases including idiopathic thrombocytopenic purpura (ITP). Several studies recently showed a high prevalence of H pylori infection in patients with ITP and reported a platelet recovery after bacterial eradication therapy. The prevalence of H pylori infection and effect of its eradication in Korea patients with chronic ITP were investigated. Methods: The study included among 35 patients with chronic ITP from eight hospitals. H pylori infection was assessed by urea breath test, rapid urease test or microbial culture. H pylori eradication was performed with amoxicillin, clarithromycin and omeprazol regimen for 7 days or bismuth, metronidazol and tetracycline regimen for 10 days. Eradication was assessed by urea breath test 4 weeks after treatment. Platelet counts were monitored serially after the end of treatment. Results: Thirty five patients with chronic ITP were evaluated, including 12 males and 23 females. Median age was 57 years (range 30–79). The median platelet count before eradication was 23,000/uL (range 4,000–66,000/uL). Sixteen patients were performed the splenectomy previously. H pylori infection was found in 23 (65%) of 35 patients. In 21 patients performed the eradication, 6 patients (28.5%) had a significant increase in platelet count after 2 weeks and 2 months. The response duration was 1–27 (median 7.6) months. Conclusions: This study confirmed the efficacy of H pylori eradication in increasing platelet in adult chronic ITP patients. We must consider the investigation and eradication of H pylori infection in ITP patients as a simple, inexpensive tool in management of the chronic disease.

scholarly journals Correlation between Quantitative 13C-Urea Breath Test and Helicobacter pylori Treatment Success in a Population-Based Cohort

2018 ◽  
Vol 2018 ◽  
pp. 1-6 ◽  
Author(s):  
Doron Boltin ◽  
Zohar Levi ◽  
Tsachi Tsadok Perets ◽  
Hemda Schmilovitz-Weiss ◽  
Rachel Gingold-Belfer ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Breath Test ◽  
Treatment Success ◽  
Population Based ◽  
Urea Breath Test ◽  
First Line Therapy ◽  
13C Urea Breath Test ◽  
Helicobacter Pylori Treatment ◽  
H Pylori ◽  
First Time

Background. There are continual efforts to identify factors which influence the success of first-line therapy for Helicobacter pylori (H. pylori) infection. The 13C-urea breath test result (C13-UBT) utilizes H. pylori urease activity and is a highly accurate diagnostic assay. We aimed to determine whether the magnitude of C13-UBT result is related to treatment success. Methods. Adult patients who underwent a first-time 13C-urea breath test between January 2010 and January 2016 were included. In order to isolate a naïve test-and-treat population who were unlikely to have undergone an initial endoscopy-based H. pylori test, we excluded patients > 45 years and those with a previous C13-UBT. Data were extracted from the Clalit Health Services laboratory database. Results. A total of 94,590 subjects (36.1% male, age 28.5 ± 6.0 years) who underwent a first-time C13-UBT during the study period were included. C13-UBT was positive in 48,509 (51.3%) subjects. A confirmatory posttreatment C13-UBT was performed in 18,375 (37.8%), and eradication was successful in 12,018 (65.4%). The mean C13-UBT recording was 20.6 ± 16.2 DOB in subjects with successful eradication and 19.5 ± 13.1 DOB in subjects with treatment failure (OR, 1.01; 95% CI 1.00-1.01, p<0.01). Among patients in the upper quintile of C13-UBT measurement, eradication was achieved in 67.6%, compared to 62.6% in the lower quintile (OR, 1.22; 95% CI 1.11-1.35, p<0.01). Subjects in the top 1 percentile (C13-UBT ≥ 70 DOB) achieved eradication in 75.0%, compared to 65.3% among subjects with C13-UBT < 70 DOB (OR, 1.59; 95% CI 1.05-2.41, p<0.01). Conclusions. The superiority in H. pylori eradication observed in subjects with a higher C13-UBT DOB is small but significant. Further studies should examine the physiological and microbiological basis for this finding.

Positive serology indicates an active H. pylori infection in patients with atrophic gastritis in spite of negative histology and 13C-urea breath test

1998 ◽  
Vol 114 ◽  
pp. A183 ◽  
Author(s):  
A. Kokkola ◽  
P. Puolakkainen ◽  
H. Rautelin ◽  
P. Sipponen ◽  
M. Färkkilä ◽  
...  
Keyword(s):  
Atrophic Gastritis ◽  
Breath Test ◽  
Urea Breath Test ◽  
Positive Serology ◽  
13C Urea Breath Test ◽  
H Pylori

Knowledge of a negative 13C-urea breath test reduces health care utilisation for dyspepsia in a population H pylori test and treat program

2000 ◽  
Vol 118 (4) ◽  
pp. A678
Author(s):  
Paul Moayyedi ◽  
Richard Feltbower ◽  
Sara Duffett ◽  
Will Crocombe ◽  
David Forman ◽  
...  
Keyword(s):  
Health Care ◽  
Breath Test ◽  
Health Care Utilisation ◽  
Urea Breath Test ◽  
Test And Treat ◽  
Care Utilisation ◽  
13C Urea Breath Test ◽  
H Pylori

scholarly journals PROSPECTIVE STUDY FOR VALIDATION OF A SINGLE PROTOCOL FOR THE 13C-UREA BREATH TEST USING TWO DIFFERENT DEVICES IN THE DIAGNOSIS OF H. PYLORI INFECTION

2019 ◽  
Vol 56 (2) ◽  
pp. 197-201 ◽  
Author(s):  
Luiz Gonzaga Vaz COELHO ◽  
Osmar Reni TRINDADE ◽  
Laiane Alves LEÃO ◽  
Henrique Gomes RIBEIRO ◽  
Izabella Silva FREITAS ◽  
...  
Keyword(s):  
Gold Standard ◽  
Breath Test ◽  
Kappa Coefficient ◽  
Urea Breath Test ◽  
Wilcoxon Test ◽  
Breath Sample ◽  
Prospective Comparison ◽  
Before And After ◽  
13C Urea Breath Test ◽  
H Pylori

ABSTRACT BACKGROUND: 13C-urea breath test (UBT) is the gold-standard, noninvasive method for H. pylori diagnosis. However, there is no uniform standardization of the test. This situation can be unpractical for laboratories running with two or more devices. OBJECTIVE: To perform a prospective comparison validation study of UBT employing one validated protocol for two different devices: BreathID Hp Lab System® (Exalenz Bioscience Ltd, Israel), here called device A and IRIS-Doc2® (Wagner Analysen-Technik, Germany, now Mayoly Spindler Group, France), here called device B, in the diagnosis of H. pylori infection. METHODS: A total of 518 consecutive patients (365 females, 153 males, mean age 53 years) referred for UBT were included. All patients received device A protocol as follow: after at least one hour fasting, patients filled two bags prior to the test, then ingested an aqueous solution containing 75 mg of 13C-urea with a 4.0 g citric acid powder and filled another two bags 15 min after ingesting the test solution. One pair of breath sample bags (before and after ingestion) was analyzed by the two different devices. A delta over baseline (DOB) ≥5‰ indicated H. pylori infection. Statistics: Wilcoxon test, kappa coefficient with 95% CI, Wilson’s method. RESULTS: Considering the device A protocol as the gold standard, its comparison with device B showed a sensitivity of 99.3% (95% CI: 96.3-99.9) and a specificity of 98.9% (95% CI: 97.3-99.6). Kappa coefficient was 0.976 (95% IC: 0.956-0.997). CONCLUSION: Correlation between the two devices was excellent and supports a uniform standardization of UBT.

Sign in / Sign up

Export Citation Format

Share Document